MGNX
$3.08
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Recent News
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of +47.31% and +71.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics: Q4 Earnings Snapshot
ROCKVILLE, Md. AP) — MacroGenics Inc. MGNX) on Monday reported a loss of $14.2 million in its fourth quarter.
BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +300.00% and +5.16%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
January 2026's Top Penny Stocks To Watch
Major stock indexes in the United States presented a mixed picture recently, with the S&P 500 reaching an all-time high while the Dow Jones Industrial Average faced downward pressure. Despite these fluctuations, investors continue to explore diverse opportunities across various sectors. Penny stocks, often associated with smaller or newer companies, remain a compelling area for those seeking affordable entry points and potential growth. These stocks can offer significant value when they are...
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.